PHR — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-28

• •Net cash provided by operating activities was $23.9 million for the three months ended April 30, 2026, as compared to $14.9 million for the three months ended April 30, 2025.

• •Cash, cash equivalents and restricted cash as of April 30, 2026 was $76.4 million, an increase of $2.6 million as compared to January 31, 2026. As of April 30, 2026, cash, cash equivalents and restricted cash included $1.7 million of long-term restricted cash classified within other long-term asset…

• Adjusted EBITDA and Free cash flow are Non-GAAP measures. For a reconciliation of Adjusted EBITDA to net income (loss) and a reconciliation of free cash flow to net cash provided by operating activities, and for more information as to how we define and calculate such measures, see the section below …

• We provide an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and health patient outcomes. Our platform is embedded directly into provider workflows and patient interactions, enabl…

• Access: Our solutions facilitate access to care by reducing friction in how patients find, schedule, and register for care, while enabling providers to improve capacity utilization and reduce administrative burden. Key capabilities include care discovery and scheduling through MediFind, our online p…

Text removed vs the prior filing · source: 10-Q · 2025-12-09

• •Net income was $1.0 million in the nine months ended October 31, 2025, as compared to net loss of $52.1 million in the nine months ended October 31, 2024.

• •Adjusted EBITDA was $72.1 million in the nine months ended October 31, 2025, as compared to $20.4 million in the nine months ended October 31, 2024.

• •Net cash provided by operating activities was $15.5 million for the three months ended October 31, 2025, as compared to $5.8 million for the three months ended October 31, 2024.

• •Net cash provided by operating activities was $45.2 million for the nine months ended October 31, 2025, as compared to $16.1 million for the nine months ended October 31, 2024.

• •Free cash flow was $8.8 million for the three months ended October 31, 2025, as compared to $1.6 million for the three months ended October 31, 2024.

Text added vs the prior filing · source: 10-Q · 2026-05-28

• As required by Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act, our management, including our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation as of the end of the period covered by this Quarterly Report of the effectiveness of the design and operation of our di…

• As disclosed in the Notes to Consolidated Financial Statements within our Annual Report on Form 10-K for the fiscal year ended January 31, 2026, we completed the AccessOne Acquisition on November 12, 2025. AccessOne’s total revenues for the three months ended April 30, 2026 constituted approximately…

Text removed vs the prior filing · source: 10-Q · 2025-12-09

• As required by Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act, our management, including our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation as of the end of the period covered by this Quarterly Report of the effectiveness of the design and operation of our di…

• 2025, our disclosure controls and procedures were effective at the reasonable assurance level in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in …

Text added vs the prior filing · source: 10-Q · 2026-05-28

• The market for our solutions and services is fragmented, competitive and characterized by rapidly evolving technology standards, evolving regulatory requirements, changes in client needs and the frequent introduction of new products and services, including as a result of AI technologies. Our competi…

• and would adversely affect our results of operations. Additionally, if we do not maintain our current client network, or if we have to renegotiate existing contracts on terms less favorable to us, our business, financial condition and results of operations may be harmed.

• We believe demand for our solutions and services has been driven in large part by increasing patient responsibility, engagement and consumerism. Our ability to streamline critical workflows in order to improve healthcare services clients’ operations and patient engagement to allow for optimal alloca…

• •our ability to obtain meaningful annualized run-rate expense savings from implementing our restructuring plan to reduce operating expenses;

• •the extent to which developments in AI may reduce demand for our solutions;

Text removed vs the prior filing · source: 10-Q · 2025-12-09

• The market for our products and services is fragmented, competitive and characterized by rapidly evolving technology standards, evolving regulatory requirements, changes in client needs and the frequent introduction of new products and services, including as a result of AI technologies. Our competit…

• companies to large, well-financed and technologically-sophisticated entities, including the EHR and PM systems with which we integrate. As costs fall and technology improves, increased market saturation may change the competitive landscape in favor of competitors with greater scale than we currently…

• We believe demand for our products and services has been driven in large part by increasing patient responsibility, engagement and consumerism. Our ability to streamline the intake process and critical workflows in order to improve healthcare services organization, staff efficiency and patient engag…

• •our ability to hire and retain qualified personnel, including the rate of expansion of our sales force;

• In addition, the number of patients utilizing our payment processing tools or consumer financing services offered by our subsidiary, AccessOne MedCard, and the amounts those patients pay directly to our healthcare services clients for services or patients’ need for extended payment plans offered thr…

Text added vs the prior filing · source: 10-Q · 2026-05-28

• None of our directors or “officers,” as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, adopted or terminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter covered…

Text removed vs the prior filing · source: 10-Q · 2025-12-09

• On September 16, 2025, Yvonne Hui, our Chief Accounting Officer, adopted a trading arrangement for the sale of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). Ms. Hui’s Rule 10b5-1 Trading Plan, which expi…